TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in October

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 62,100 shares, an increase of 21.3% from the September 30th total of 51,200 shares. Based on an average daily volume of 47,100 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.4% of the company's stock are sold short.

Analyst Ratings Changes

Several equities analysts have weighed in on TLSI shares. Oppenheimer initiated coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an "outperform" rating and a $10.00 price objective for the company. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday. They issued an "outperform" rating and a $12.50 price target on the stock. Finally, Northland Capmk upgraded TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $12.50.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares of the company's stock, valued at $1,962,386.40. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 32.80% of the company's stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in TLSI. Highbridge Capital Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $1,184,000. Duquesne Family Office LLC grew its position in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after buying an additional 110,966 shares during the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $240,000. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Price Performance

TLSI stock traded down $0.08 during midday trading on Monday, reaching $3.99. 32,163 shares of the stock were exchanged, compared to its average volume of 22,348. The stock has a market capitalization of $116.95 million, a PE ratio of -1.60 and a beta of 0.47. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42. The company has a fifty day moving average price of $4.67 and a 200 day moving average price of $6.30.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $7.36 million during the quarter. As a group, analysts anticipate that TriSalus Life Sciences will post -1.53 earnings per share for the current fiscal year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.